Serum Activin A as Brain Injury Biomarker in the First Three Days of Life. A Prospective Case—Control Longitudinal Study in Human Premature Neonates

Metallinou, Dimitra; Karampas, Grigorios; Lazarou, Eleftheria; Iacovidou, Nikoletta; Pervanidou, Panagiota; Lykeridou, Katerina; Mastorakos, George; Rizos, Demetrios

doi:10.3390/brainsci11091243

Cited by 6 publications

(7 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This prospective longitudinal case-control study is part of a larger research protocol that investigates NBI biomarkers in preterm neonates [5,19,28]. This study is based on methods previously published and is outlined below:…”

Section: Methodsmentioning

confidence: 99%

Serum Neuron-Specific Enolase as a Biomarker of Neonatal Brain Injury—New Perspectives for the Identification of Preterm Neonates at High Risk for Severe Intraventricular Hemorrhage

Metallinou,

Karampas,

Pavlou

et al. 2024

Biomolecules

Self Cite

View full text Add to dashboard Cite

Neonatal brain injury (NBI) is a critical condition for preterm neonates with potential long-term adverse neurodevelopmental outcomes. This prospective longitudinal case–control study aimed at investigating the levels and prognostic value of serum neuron-specific enolase (NSE) during the first 3 days of life in preterm neonates (<34 weeks) that later developed brain injury in the form of either periventricular leukomalacia (PVL) or intraventricular hemorrhage (IVH) during their hospitalization. Participants were recruited from one neonatal intensive care unit, and on the basis of birth weight and gestational age, we matched each case (n = 29) with a neonate who had a normal head ultrasound scan (n = 29). We report that serum NSE levels during the first three days of life do not differ significantly between control and preterm neonates with NBI. Nevertheless, subgroup analysis revealed that neonates with IVH had significantly higher concentrations of serum NSE in comparison to controls and neonates with PVL on the third day of life (p = 0.014 and p = 0.033, respectively). The same pattern on the levels of NSE on the third day of life was also observed between (a) neonates with IVH and all other neonates (PVL and control; p = 0.003), (b) neonates with II–IV degree IVH and all other neonates (p = 0.003), and (c) between control and the five (n = 5) neonates that died from the case group control (p = 0.023). We conclude that NSE could be an effective and useful biomarker on the third day of life for the identification of preterm neonates at high risk of developing severe forms of IVH.

show abstract

Section: Methodsmentioning

confidence: 99%

Serum Neuron-Specific Enolase as a Biomarker of Neonatal Brain Injury—New Perspectives for the Identification of Preterm Neonates at High Risk for Severe Intraventricular Hemorrhage

Metallinou,

Karampas,

Pavlou

et al. 2024

Biomolecules

Self Cite

View full text Add to dashboard Cite

show abstract

“…The health and quality of life of middle-aged and older individuals are affected by neurodegenerative disorders such as Parkinson's and Alzheimer's (123). Nanogel has great potential as a delivery vehicle for oligodeoxynucleotides (ODN) to the brain, particularly for the treatment of neurodegenerative disorders.…”

Section: Hydrogels: Applications In Cnsmentioning

confidence: 99%

Hydrogel nanoparticles as new drug delivery system for CNS disorders

Omar Khudhur,

Karimian,

Asadi

et al. 2024

ChemistrySelect

View full text Add to dashboard Cite

Previous studies have shown that more than one million individuals suffer from central nervous system (CNS) diseases worldwide. Nanogels are a good way to deliver drugs because they are ultra‐stable, can hold a lot of drugs, have a core‐shell structure, are very permeable, and can get into brain tissue both in the lab and in living organisms. The blood‐brain barrier (BBB) and the blood‐cerebrospinal fluid barrier (BCSFB) make it harder to deliver therapies to specific areas of the CNS because drugs can′t get into the brain well enough. However, these barriers help treat neurological disorders like epilepsy, neurodegenerative diseases, brain tumors, and ischemic stroke. A number of biological studies suggest that nano‐additives may improve the shape, mechanical properties, electrical conductivity, and biological activities of hydrogels. The creation of nanogels for CNS drug delivery, their early preclinical success, and their potential for neurotoxicity are all examined in this research. This study looks at techniques that are almost ready for clinical use, a preclinical delivery system for the CNS, and the use of nanogels as a successful BBB‐penetration method. It also examines the main difficulties that nanogels must overcome in order to provide the most effective therapeutic care for CNS illnesses.

show abstract

“…Neonatal brain injury (NBI) refers to damage or abnormalities in the brain of a neonate, typically occurring within the first few days or weeks of life. In neonates, NBI is a leading cause of mortality and morbidity and is strongly associated with significant impacts on the child's development and long-term adverse neurological outcomes [1,2]. There are several potential causes of NBI but it is usually a complex and multifactorial clinical situation.…”

Section: Introductionmentioning

confidence: 99%

Future perspectives on neonatal brain injury

Maria Tzeli,

Maria Tigka,

Nikoletta Pantelaki

et al. 2023

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Neonatal brain injury (NBI) is a complex and challenging area of research and critical care. Advances in understanding and treating NBI are crucial for improving the long-term adverse neurological outcomes of the affected neonates. Future perspectives in NBI are focused on systematic antenatal education, personalized medicine and profiling, stem cell and neuroprotective therapies, biomarkers in biological fluids with an emphasis on multimodal biomarker panels, collaborative research projects and considerations regarding ethical issues. Although substantial efforts have been made recently to restrain NBI, its incidence is still high on a global scale. Therefore, future management of NBI will involve a multidisciplinary approach that integrates genetics, individualized therapy, and medical advancements, with particular attention to early detection and intervention. The ultimate goal is to reduce the prevalence of NBI and improve the affected neonates' long-term prognosis. It is critical to remember that this field of study is still being investigated, and it could be years before many of these advancements are widely applied in standard clinical practice.

show abstract

Serum Activin A as Brain Injury Biomarker in the First Three Days of Life. A Prospective Case—Control Longitudinal Study in Human Premature Neonates

Cited by 6 publications

References 38 publications

Serum Neuron-Specific Enolase as a Biomarker of Neonatal Brain Injury—New Perspectives for the Identification of Preterm Neonates at High Risk for Severe Intraventricular Hemorrhage

Serum Neuron-Specific Enolase as a Biomarker of Neonatal Brain Injury—New Perspectives for the Identification of Preterm Neonates at High Risk for Severe Intraventricular Hemorrhage

Hydrogel nanoparticles as new drug delivery system for CNS disorders

Future perspectives on neonatal brain injury

Contact Info

Product

Resources

About